Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model

BACKGROUND: Both modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in patients with pancreatic cancer, and are often used interchangeably as the standard of care. Preclinical studies often do not use these regimens, since adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Delahoussaye, Abagail M., Abi Jaoude, Joseph, Green, Morgan, Fujimoto, Tara N., Molkentine, Jessica, Garcia Garcia, Carolina J., Gay, Jason P., Feng, Ningping, Marszalek, Joseph, Fowlkes, Natalie, Taniguchi, Cullen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848646/
https://www.ncbi.nlm.nih.gov/pubmed/35172762
http://dx.doi.org/10.1186/s12885-022-09255-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848646/
https://www.ncbi.nlm.nih.gov/pubmed/35172762
http://dx.doi.org/10.1186/s12885-022-09255-3

Ejemplares similares